Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Sep;10(5):e002894.
doi: 10.1136/bmjdrc-2022-002894.

Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes

Xin Tang  1 , Roberta Diaz Brinton  2 , Zhao Chen  1 , Leslie V Farland  1 , Yann Klimentidis  3 , Raymond Migrino  4   5 , Peter Reaven  5   6 , Kathleen Rodgers  7 , Jin J Zhou  8   9
Affiliations
Observational Study

Use of oral diabetes medications and the risk of incident dementia in US veterans aged ≥60 years with type 2 diabetes

Xin Tang et al. BMJ Open Diabetes Res Care. 2022 Sep.

Abstract

Introduction: Studies have reported that antidiabetic medications (ADMs) were associated with lower risk of dementia, but current findings are inconsistent. This study compared the risk of dementia onset in patients with type 2 diabetes (T2D) treated with sulfonylurea (SU) or thiazolidinedione (TZD) to patients with T2D treated with metformin (MET).

Research design and methods: This is a prospective observational study within a T2D population using electronic medical records from all sites of the Veterans Affairs Healthcare System. Patients with T2D who initiated ADM from January 1, 2001, to December 31, 2017, were aged ≥60 years at the initiation, and were dementia-free were identified. A SU monotherapy group, a TZD monotherapy group, and a control group (MET monotherapy) were assembled based on prescription records. Participants were required to take the assigned treatment for at least 1 year. The primary outcome was all-cause dementia, and the two secondary outcomes were Alzheimer's disease and vascular dementia, defined by International Classification of Diseases (ICD), 9th Revision, or ICD, 10th Revision, codes. The risks of developing outcomes were compared using propensity score weighted Cox proportional hazard models.

Results: Among 559 106 eligible veterans (mean age 65.7 (SD 8.7) years), the all-cause dementia rate was 8.2 cases per 1000 person-years (95% CI 6.0 to 13.7). After at least 1 year of treatment, TZD monotherapy was associated with a 22% lower risk of all-cause dementia onset (HR 0.78, 95% CI 0.75 to 0.81), compared with MET monotherapy, and 11% lower for MET and TZD dual therapy (HR 0.89, 95% CI 0.86 to 0.93), whereas the risk was 12% higher for SU monotherapy (HR 1.12 95% CI 1.09 to 1.15).

Conclusions: Among patients with T2D, TZD use was associated with a lower risk of dementia, and SU use was associated with a higher risk compared with MET use. Supplementing SU with either MET or TZD may partially offset its prodementia effects. These findings may help inform medication selection for elderly patients with T2D at high risk of dementia.

Keywords: Dementia; Preventive Medicine.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Cohort assembling process for the primary analysis. HbA1c, glycated hemoglobin; MET, metformin; SU, sulfonylurea; T2D, type 2 diabetes; TZD, thiazolidinedione; VA, Veteran Affairs.
Figure 2
Figure 2
Timeline and schema of the study. MET, metformin; SU, sulfonylurea; TZD, thiazolidinedione; VA, Veteran Affairs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Organization WH . Global status report on the public health response to dementia 2021.
    1. Cheng G, Huang C, Deng H, et al. . Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J 2012;42:484–91. 10.1111/j.1445-5994.2012.02758.x - DOI - PubMed
    1. Ott A, Stolk RP, van Harskamp F, et al. . Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 1999;53:1937–42. 10.1212/WNL.53.9.1937 - DOI - PubMed
    1. Sims-Robinson C, Kim B, Rosko A, et al. . How does diabetes accelerate Alzheimer disease pathology? Nat Rev Neurol 2010;6:551–9. 10.1038/nrneurol.2010.130 - DOI - PMC - PubMed
    1. Hsu C-C, Wahlqvist ML, Lee M-S, et al. . Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J Alzheimers Dis 2011;24:485–93. 10.3233/JAD-2011-101524 - DOI - PubMed

Publication types

MeSH terms